Business Context and Reporting Period
This Form 8-K filing by Varex Imaging Corporation (VREX) reports a material executive transition event. The report date is September 5, 2025, with the document signed on September 11, 2025.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the departure of Kimberley Honeysett from her role as Senior Vice President, Chief Legal Officer, and Corporate Secretary (CLO). Key terms of the transition include:
- Transition Period: Ms. Honeysett remains CLO until October 3, 2025, receiving her current salary and benefits.
- Continued Service Period: From October 4, 2025, through December 12, 2027, she will serve as a non-executive employee or advisor reporting to the CEO.
- Compensation Structure:
- Fiscal Year 2026: Full annual salary, eligibility for management incentive plan bonus, and standard benefits.
- Post-Fiscal Year 2026: Fixed compensation of $100,000 plus continued health insurance and other outlined benefits.
- Equity: Existing equity awards will continue to vest; no new equity grants are eligible.
- Insurance: Coverage under the Directors and Officers insurance policy continues until full transition from all officer and director roles.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. The only contingency noted is the Company's right to terminate the Transition Agreement at any time for "Cause" as defined in the agreement. The agreement includes mutual general releases and indemnification provisions.
Investor Verification Checklist
- Confirm the exact end date of the Continued Service Period (December 12, 2027) and the specific scope of services required.
- Verify the definition of "Cause" within the Transition Agreement to understand termination risks.
- Review the specific vesting schedule of Ms. Honeysett's outstanding equity awards to assess potential dilution or expense recognition.
- Monitor subsequent filings for the appointment of a permanent replacement for the CLO role.